CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes
BOSTON, March 17, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical…
BOSTON, March 17, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical…
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX),…
TORONTO, March 17, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB:…
GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr)…
IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial…
VANCOUVER, British Columbia, March 17, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the…
JENA, Germany, March 17, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical…
CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 2022…
CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the…
LEAMINGTON, Ontario, March 17, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”)…
TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc….
WINNIPEG, Manitoba, March 17, 2022 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the…
NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ:…
Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for…
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage…
-FYARRO™ approved November 22, 2021 and launched February 23, 2022- –FYARRO added to NCCN® Guidelines…
Harmony remains ongoing, with OLE study intended to gain insights into long-term exposure to ADP101…
Over $140M in capital raised in initial public offering in 2021; Cash runway through first…
FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support potential commercial…
– DesCAARTes™ trial progressing in cohort A5 with presentation of DSG3-CAART clinical and translational data…